Skip to main content

Table 3 Antibiotic susceptibility of M. abscessus isolates.*

From: Effectiveness and safety of regimens containing linezolid for treatment of Mycobacterium abscessus pulmonary Disease

Drug

Total (n = 336)

Linezolid group (n = 164)

Control group (n = 172)

χ2

P value

S

I

R

S

I

R

S

I

R

AMK

306

(91.1)

12

(3.6)

18

(5.3)

150

(91.5)

6

(3.6)

8

(4.9)

156

(90.7)

6

(3.5)

10

(5.8)

0.149

0.928

FOX

44

(13.1)

169

(50.3)

123

(36.6)

20

(12.2)

81

(49.4)

63

(38.4)

24

(14.0)

88

(51.2)

60

(34.8)

0.537

0.765

CIP

19

(5.6)

5

(1.5)

312

(92.9)

11

(6.7)

3

(1.8)

150

(91.5)

8

(4.6)

2

(1.2)

162

(94.2)

0.694

0.707

CLR

143

(42.6)

12

(3.6)

181

(53.8)

69

(42.1)

6

(3.7)

89

(54.2)

74

(43.0)

6

(3.5)

92

(53.5)

0.034

0.983

DOX

41

(12.2)

16

(4.8)

269

(80.0)

22

(13.4)

7

(4.3)

135

(82.3)

19

(11.1)

9

(5.2)

144

(83.7)

0.570

0.752

IMP

8

(2.4)

15

(4.5)

313

(93.1)

4

(2.4)

8

(4.9)

152

(92.7)

4

(2.3)

7

(4.1)

161

(93.6)

0.135

0.935

LZD

166

(49.4)

10

(3.0)

160

(47.6)

159

(97.0)

4

(2.4)

1

(0.6)

7

(4.1)

6

(3.5)

159

(92.4)

295.583

< 0.001

MNO

64

(19.0)

36

(10.7)

236

(70.3)

36

(22.0)

15

(9.1)

113

(68.9)

28

(16.3)

21

(12.2)

123

(71.5)

2.235

0.327

MFX

14

(4.2)

4

(1.2)

318

(94.6)

7

(4.3)

1

(0.6)

156

(95.1)

7

(4.1)

3

(1.7)

162

(94.2)

0.923

0.630

TOB

50

(14.9)

46

(13.7)

240

(71.4)

25

(15.2)

20

(12.2)

119

(72.6)

25

(14.5)

26

(15.1)

121

(70.4)

0.609

0.737

SOX

16

(4.8)

-

-

320

(95.2)

8

(4.9)

-

-

156

(95.1)

8

(4.7)

-

-

164

(95.3)

0.01

0.922

  1. *Numbers indicate n (%)
  2. S, susceptible; I, intermediate; R, resistant; AMK, amikacin; FOX, cefoxitin; CIP, ciprofloxacin; CLR, clarithromycin; DOX, doxycycline; IMP, imipenem; LZD, linezolid; MNO, minocycline; MFX, moxifloxacin; TOB, tobramycin; SOX, sulfamethoxazole